The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.
Histologically or cytologically confirmed malignant digestive system tumors;
Patients with advanced recurrent, unresectable and / or metastatic digestive system tumors who have failed standard or conventional treatment:( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment);
Eastern Cooperative Oncology Group performance status score of 0 or 1;
Life expectancy > 12 weeks;
Any patient who is known to have central nervous system (CNS) metastasis with clinical symptoms;
Other kinds of malignancies;
Gastrointestinal abnormalitiest;
Cardiovascular and cerebrovascular diseases;